Literature DB >> 35746526

Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences.

Reem Hoteit1, Hadi M Yassine2.   

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a virus that belongs to the coronavirus family and is the cause of coronavirus disease 2019 (COVID-19). As of May 2022, it had caused more than 500 million infections and more than 6 million deaths worldwide. Several vaccines have been produced and tested over the last two years. The SARS-CoV-2 virus, on the other hand, has mutated over time, resulting in genetic variation in the population of circulating variants during the COVID-19 pandemic. It has also shown immune-evading characteristics, suggesting that vaccinations against these variants could be potentially ineffective. The purpose of this review article is to investigate the key variants of concern (VOCs) and mutations of the virus driving the current pandemic, as well as to explore the transmission rates of SARS-CoV-2 VOCs in relation to epidemiological factors and to compare the virus's transmission rate to that of prior coronaviruses. We examined and provided key information on SARS-CoV-2 VOCs in this study, including their transmissibility, infectivity rate, disease severity, affinity for angiotensin-converting enzyme 2 (ACE2) receptors, viral load, reproduction number, vaccination effectiveness, and vaccine breakthrough.

Entities:  

Keywords:  clinical consequences; coronavirus disease 2019 (COVID-19); epidemiological factors; mutations; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); variants of concern (VOCs)

Year:  2022        PMID: 35746526      PMCID: PMC9230982          DOI: 10.3390/vaccines10060919

Source DB:  PubMed          Journal:  Vaccines (Basel)        ISSN: 2076-393X


  387 in total

1.  Omicron overpowers key COVID antibody treatments in early tests.

Authors:  Max Kozlov
Journal:  Nature       Date:  2021-12-21       Impact factor: 49.962

2.  Epidemiology of respiratory infections among adults in Qatar (2012-2017).

Authors:  Hamad Eid Al-Romaihi; Maria K Smatti; Nandakumar Ganesan; Shazia Nadeem; Elmoubasher Farag; Peter V Coyle; Joanne Daghfal Nader; Hebah A Al-Khatib; Emad B Elmagboul; Said Al Dhahry; Salih A Al-Marri; Asmaa A Al Thani; Abdullatif Al Khal; Muna A Al Maslamani; Hadi M Yassine
Journal:  PLoS One       Date:  2019-06-13       Impact factor: 3.240

3.  Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.

Authors:  Anthony C Gordon; Paul R Mouncey; Farah Al-Beidh; Kathryn M Rowan; Alistair D Nichol; Yaseen M Arabi; Djillali Annane; Abi Beane; Wilma van Bentum-Puijk; Lindsay R Berry; Zahra Bhimani; Marc J M Bonten; Charlotte A Bradbury; Frank M Brunkhorst; Adrian Buzgau; Allen C Cheng; Michelle A Detry; Eamon J Duffy; Lise J Estcourt; Mark Fitzgerald; Herman Goossens; Rashan Haniffa; Alisa M Higgins; Thomas E Hills; Christopher M Horvat; Francois Lamontagne; Patrick R Lawler; Helen L Leavis; Kelsey M Linstrum; Edward Litton; Elizabeth Lorenzi; John C Marshall; Florian B Mayr; Daniel F McAuley; Anna McGlothlin; Shay P McGuinness; Bryan J McVerry; Stephanie K Montgomery; Susan C Morpeth; Srinivas Murthy; Katrina Orr; Rachael L Parke; Jane C Parker; Asad E Patanwala; Ville Pettilä; Emma Rademaker; Marlene S Santos; Christina T Saunders; Christopher W Seymour; Manu Shankar-Hari; Wendy I Sligl; Alexis F Turgeon; Anne M Turner; Frank L van de Veerdonk; Ryan Zarychanski; Cameron Green; Roger J Lewis; Derek C Angus; Colin J McArthur; Scott Berry; Steve A Webb; Lennie P G Derde
Journal:  N Engl J Med       Date:  2021-02-25       Impact factor: 91.245

Review 4.  Corona Viruses: A Review on SARS, MERS and COVID-19.

Authors:  Nihala Naseefa Chathappady House; Sheeba Palissery; Honey Sebastian
Journal:  Microbiol Insights       Date:  2021-03-19

5.  Linked Clusters of SARS-CoV-2 Variant B.1.351 - Maryland, January-February 2021.

Authors:  Kenneth A Feder; Marcia Pearlowitz; Alexandra Goode; Monique Duwell; Thelonious W Williams; Ping An Chen-Carrington; Ami Patel; Catherine Dominguez; Eric N Keller; Liore Klein; Alessandra Rivera-Colon; Heba H Mostafa; C Paul Morris; Neil Patel; Anna M Schauer; Robert Myers; David Blythe; Katherine A Feldman
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2021-04-30       Impact factor: 17.586

6.  Antibody evasion by the P.1 strain of SARS-CoV-2.

Authors:  Wanwisa Dejnirattisai; Daming Zhou; Piyada Supasa; Chang Liu; Alexander J Mentzer; Helen M Ginn; Yuguang Zhao; Helen M E Duyvesteyn; Aekkachai Tuekprakhon; Rungtiwa Nutalai; Beibei Wang; César López-Camacho; Jose Slon-Campos; Thomas S Walter; Donal Skelly; Sue Ann Costa Clemens; Felipe Gomes Naveca; Valdinete Nascimento; Fernanda Nascimento; Cristiano Fernandes da Costa; Paola Cristina Resende; Alex Pauvolid-Correa; Marilda M Siqueira; Christina Dold; Robert Levin; Tao Dong; Andrew J Pollard; Julian C Knight; Derrick Crook; Teresa Lambe; Elizabeth Clutterbuck; Sagida Bibi; Amy Flaxman; Mustapha Bittaye; Sandra Belij-Rammerstorfer; Sarah C Gilbert; Miles W Carroll; Paul Klenerman; Eleanor Barnes; Susanna J Dunachie; Neil G Paterson; Mark A Williams; David R Hall; Ruben J G Hulswit; Thomas A Bowden; Elizabeth E Fry; Juthathip Mongkolsapaya; Jingshan Ren; David I Stuart; Gavin R Screaton
Journal:  Cell       Date:  2021-03-30       Impact factor: 41.582

7.  Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022.

Authors:  Lamprini Veneti; Håkon Bøås; Anja Bråthen Kristoffersen; Jeanette Stålcrantz; Karoline Bragstad; Olav Hungnes; Margrethe Larsdatter Storm; Nina Aasand; Gunnar Rø; Jostein Starrfelt; Elina Seppälä; Reidar Kvåle; Line Vold; Karin Nygård; Eirik Alnes Buanes; Robert Whittaker
Journal:  Euro Surveill       Date:  2022-01

8.  SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness.

Authors:  Aziz Sheikh; Jim McMenamin; Bob Taylor; Chris Robertson
Journal:  Lancet       Date:  2021-06-14       Impact factor: 79.321

9.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.

Authors:  Zunyou Wu; Jennifer M McGoogan
Journal:  JAMA       Date:  2020-04-07       Impact factor: 56.272

View more
  4 in total

Review 1.  Immunity after COVID-19 Recovery and Vaccination: Similarities and Differences.

Authors:  Dorota Kamińska; Dominika Dęborska-Materkowska; Katarzyna Kościelska-Kasprzak; Oktawia Mazanowska; Agata Remiorz; Paweł Poznański; Magdalena Durlik; Magdalena Krajewska
Journal:  Vaccines (Basel)       Date:  2022-07-03

2.  Effectiveness of Comirnaty® Vaccine and Correlates of Immunogenicity and Adverse Reactions: A Single-Center Prospective Case Series Study.

Authors:  Diego Fernández-Lázaro; Manuel Garrosa; Nerea Sánchez-Serrano; Evelina Garrosa; Elena Jiménez-Callejo; María Dolores Pardo Yanguas; Juan Mielgo-Ayuso; Jesús Seco-Calvo
Journal:  Vaccines (Basel)       Date:  2022-07-22

3.  Within-host diversity of SARS-CoV-2 lineages and effect of vaccination.

Authors:  Leo Poon; Haogao Gu; Ahmed Abdul Quadeer; Pavithra Krishnan; Lydia Chang; Gigi Liu; Daisy Ng; Samuel Cheng; Tommy Tsan-Yuk Lam; Malik Peiris; Matthew McKay
Journal:  Res Sq       Date:  2022-08-11

4.  Long-Term Longitudinal Analysis of Neutralizing Antibody Response to Three Vaccine Doses in a Real-Life Setting of Previously SARS-CoV-2 Infected Healthcare Workers: A Model for Predicting Response to Further Vaccine Doses.

Authors:  Saverio Giuseppe Parisi; Carlo Mengoli; Monica Basso; Ilaria Vicenti; Francesca Gatti; Renzo Scaggiante; Lia Fiaschi; Federica Giammarino; Marco Iannetta; Vincenzo Malagnino; Daniela Zago; Filippo Dragoni; Maurizio Zazzi
Journal:  Vaccines (Basel)       Date:  2022-08-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.